...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of pharmacy technology: jPT : official publication of the Association of Pharmacy Technicians >Impact of β-blocker chances during heart failure exacerbation
【24h】

Impact of β-blocker chances during heart failure exacerbation

机译：心力衰竭加重期间β受体阻滞剂机会的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Although β-blockers are important life-saving medications in heart failure patients, studies evaluating β-blocker dosing in decompensated heart failure are limited. Objective: To determine the clinical outcomes in patients with severe decompensated heart failure receiving the same dose of β-blockers as well as those whose outpatient regimen was altered. Methods: A retrospective chart analysis was conducted in patients with severe decompensated heart failure receiving chronic β-blocker therapy who were admitted to the hospital for decompensated heart failure. Of 245 patients identified, 76 were included in the study: same dose (n = 26), decreased dose (n = 19), discontinued dose (n = 21), or increased dose (n = 10). X2 Analysis for K-independent samples evaluated the incidence of proarrhythmic events, mortality, and the number of recurrent hospitalizations after the index admission. Stepwise forward linear regression analysis determined the variables correlated with morbidity and mortality in these patients. Results: New arrhythmias during hospital admission occurred in 19 (25%) patients. The discontinued dose group had the most proarrhythmic events (47.6%; n = 10) and the most deaths (50%) in 6 months. Arrhythmias developed 1.8 and 3 days following β-blocker discontinuation or dosage reduction, respectively. Conclusions: Patients who remained on their outpatient β-blocker dose upon admission for decompensated heart failure had better clinical outcomes than others whose β-blocker dose was changed. A prospective, randomized, controlled clinical trial is warranted to further explore the implications of this drug-disease state interaction.
机译：背景：尽管β受体阻滞剂在心力衰竭患者中是重要的挽救生命的药物，但评估失代偿性心力衰竭中β受体阻滞剂剂量的研究仍然有限。目的：确定接受相同剂量的β受体阻滞剂以及门诊治疗方案改变的严重失代偿性心力衰竭患者的临床结局。方法：对接受慢性β-受体阻滞剂治疗的严重失代偿性心力衰竭患者（因失代偿性心力衰竭入院）进行回顾性图表分析。在确定的245位患者中，有76位被纳入研究：相同剂量（n = 26），降低剂量（n = 19），停药（n = 21）或增加剂量（n = 10）。 X2分析（不依赖K的样本）评估了进入指数后的心律失常事件的发生率，死亡率以及再次住院的次数。逐步正向线性回归分析确定了这些患者的发病率和死亡率相关的变量。结果：住院期间发生新的心律失常的患者为19名（25％）。停药组在6个月内发生最多的心律失常事件（47.6％; n = 10），并且死亡最多（50％）。心律失常分别在停用β受体阻滞剂或减少剂量后1.8天和3天出现。结论：入院时因失代偿性心力衰竭仍保持门诊使用β受体阻滞剂剂量的患者比改变了β受体阻滞剂剂量的患者的临床结局更好。有必要进行前瞻性，随机，对照的临床试验，以进一步探讨这种药物-疾病状态相互作用的含义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号